QCR has a study for moderate to severe COPD patients, evaluating the efficacy, safety and tolerability of Dupilumab, an investigational biological monoclonal antibody.
The study has 2 treatment arms: Dupilumab and placebo and patients will be randomized in a 1:1 fashion. Dupilumab and placebo are administered as subcutaneous injections once every 2 weeks, for up to 52 weeks. Participation in the trial will last a total of approximately 68 weeks (4 weeks screening (+/1 week) + 52 weeks treatment + 12 weeks follow up). Patients must be willing to remain on their established pre-study medication for COPD, throughout the study. Subject will be compensated 110 for each completed visit and all pre-study medication will be covered by the sponsor.
• Must be 40-85
• Diagnosis of COPD for at least 1 year
• May be a current or former smoker
• No other lung condition or diseases, including asthma